Frazier Life Sciences II prices $75 million IPO on Nasdaq
- Priced IPO of 7,500,000 Class A ordinary shares at $10.00 each
- Total offering size stands at $75,000,000
- Listing on Nasdaq under ticker FLSC begins October 14, 2026
- Jefferies serves as the sole book-running manager
- Strategy focuses on biotechnology sector acquisitions
*this image is generated using AI for illustrative purposes only.
Frazier Life Sciences Acquisition Corp. II priced its initial public offering of $75,000,000 at $10.00 per share. The special purpose acquisition company will list on The Nasdaq Capital Market under the ticker "FLSC" on October 14, 2026.
The offering comprises 7,500,000 Class A ordinary shares and is expected to close on October 15, 2026, subject to customary closing conditions. Jefferies acts as the sole book-running manager for the transaction.
Offering details
| Metric | Value |
|---|---|
| Total size | $75,000,000 |
| Share price | $10.00 |
| Shares offered | 7,500,000 |
| Ticker | FLSC |
| Listing date | October 14, 2026 |
| Closing date | October 15, 2026 |
Strategic focus and leadership
The company is sponsored by Frazier Life Sciences Holdings II, LLC, an affiliate of Frazier Life Sciences Management, L.P. It is led by Chief Executive Officer Albert Cha, M.D., Ph.D., Chairman of the Board Ben Palleiko, and Chief Business Officer Kevin Li, M.D.
While the entity may pursue acquisition opportunities in any business or sector, it intends to leverage its management team's experience to identify opportunities in the biotechnology sector. The stated goal is financing companies developing new therapies while creating value for shareholders.
Regulatory status
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 13, 2026. The offering is made only by means of a prospectus.
Which specific biotechnology companies or therapeutic areas are currently on Frazier Life Sciences' shortlist for acquisition?
How will the $75 million trust size influence the scale and stage of biotech targets compared to larger SPACs?
What impact might recent FDA regulatory shifts have on the valuation of potential target companies in this sector?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
